Latest Breaking News On - Federated hermes kaufmann funds - Page 3 : comparemela.com

Why Minerva Neurosciences Stock Is Shooting Higher Today

Why Minerva Neurosciences Stock Is Shooting Higher Today
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Boehringer ingelheimMinerva neurosciences incMinerva neurosciencesFederated hermes kaufmann funds

Minerva Neurosciences, Inc: Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

Minerva Neurosciences, Inc: Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesMinerva neurosciencesHelen shikFrederick ahlholmMinerva neurosciences incExchange commission onExchange commissionShik communicationsBoehringer ingelheimFederated hermes kaufmann fundsSecurities actPrivate securities litigation reform actAnnual reportQuarterly report

Minerva Neurosciences (NERV) Prices $20M Offering at $10/sh

Minerva Neurosciences (NERV) Prices $20M Offering at $10/sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHelen shikMinerva neurosciencesFrederick ahlholmExchange commission onExchange commissionShik communicationsBoehringer ingelheimMinerva neurosciences incFederated hermes kaufmann fundsSecurities actPrivate securities litigation reform actAnnual reportQuarterly report

Why Minerva Neurosciences (NERV) Stock Is Shooting Higher Today - Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences, Inc (NASDAQ: NERV) are shooting higher after the company bagged a $20 million investment from Boehringer Ingelheim and Federated Hermes Kaufmann Funds via 

Minerva neurosciences incDrug administrationBoehringer ingelheimMinerva neurosciencesFederated hermes kaufmann fundsNew drug application

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates

FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society.

United statesAmanda crayDmitri bobilevJohn valliantFusion pharmaceuticals incPrnewswire fusion pharmaceuticals incInvestor relations corporate communicationsDrug administrationFusion pharmaceuticalsNiowave incExchange commissionSociety of nuclear medicineNuclear medicineMolecular imagingFederated hermes kaufmann fundsExecutive officer john valliant